Jennings William C, Sideman Matthew J, Taubman Kevin E, Broughan Thomas A
Department of Surgery, University of Oklahoma College of Medicine, Tulsa, OK, USA.
J Vasc Surg. 2009 Nov;50(5):1121-5; discussion 1125-6. doi: 10.1016/j.jvs.2009.07.077. Epub 2009 Sep 26.
An arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis, offering lower morbidity, mortality, and cost compared with grafts or catheters. Patients with a difficult access extremity have often lost all superficial veins, and even basilic veins may be obliterated. We have used brachial vein transposition AVFs (BVT-AVFs) in these challenging patients and review our experience in this report.
The study reviewed consecutive patients in whom BVT-AVFs were created from September 2006 to March 2009. Most BVT-AVFs were created in staged procedures, with the second-stage transposition operations completed 4 to 6 weeks after the first-stage AVF operation. A single-stage BVT-AVF was created when the brachial vein diameter was > or =6 mm.
We identified 58 BVT-AVF procedures, comprising 41 women (71.0%), 28 diabetic patients (48.3%), and 29 (50.0%) had previous access surgery. The operation was completed in two stages in 45 operations (77.6%) and was a primary transposition in 13 patients. However, five of these were secondary AVFs with previous distal AV grafts or AVFs placed elsewhere; effectively, late staged procedures. Follow-up was a mean of 11 months (range, 2.0-31.7 months). Primary patency, primary-assisted patency, and cumulative (secondary) patency were 52.0%, 84.9%, and 92.4% at 12 months and 46.2%, 75.5%, and 92.4% at 24 months, respectively. Harvesting the brachial vein was tedious and more difficult than harvesting other superficial veins. No prosthetic grafts were used.
BVT-AVFs provide a suitable option for autogenous access when the basilic vein is absent in patients with difficult access extremities. Most patients required intervention for access maturation or maintenance. Most BVT-AVFs were created with staged procedures. Cumulative (secondary) patency was 92.4% at 24 months.
动静脉内瘘(AVF)是血液透析首选的血管通路,与移植血管或导管相比,其发病率、死亡率和成本更低。血管通路困难的患者常常已失去所有浅表静脉,甚至贵要静脉也可能闭塞。我们在这些具有挑战性的患者中使用了肱静脉转位动静脉内瘘(BVT-AVF),并在本报告中回顾我们的经验。
本研究回顾了2006年9月至2009年3月期间连续接受BVT-AVF手术的患者。大多数BVT-AVF手术分阶段进行,第二阶段转位手术在第一阶段AVF手术后4至6周完成。当肱静脉直径≥6mm时,进行单阶段BVT-AVF手术。
我们确定了58例BVT-AVF手术,其中包括41名女性(71.0%),28名糖尿病患者(48.3%),29名(50.0%)曾接受过血管通路手术。45例手术(77.6%)分两个阶段完成,13例患者进行了一期转位。然而,其中5例是二次动静脉内瘘,之前有远端动静脉移植血管或在其他部位放置了动静脉内瘘;实际上是晚期分阶段手术。平均随访时间为11个月(范围2.0 - 31.7个月)。12个月时的初次通畅率、初次辅助通畅率和累积(二次)通畅率分别为52.0%、84.9%和92.4%,24个月时分别为46.2%、75.5%和92.4%。采集肱静脉比采集其他浅表静脉更繁琐、更困难。未使用人工血管移植物。
对于血管通路困难且贵要静脉缺失的患者,BVT-AVF为自体血管通路提供了一个合适的选择。大多数患者需要进行干预以促进血管通路成熟或维持。大多数BVT-AVF手术分阶段进行。24个月时累积(二次)通畅率为92.4%。